Symrise AG
5-year stock timeline
Symrise has spent the past five years building scale through acquisition while learning to prove it can execute. The stock—now at €81.86—tells that story in its moves.
Between 2020 and 2021, the market loved the narrative: a flavors and fragrances company expanding into pet nutrition, naturals, and fine fragrance. The acquisitions came fast—Sensient's fragrance and aroma chemicals in late 2020, Giraffe Foods in December 2021—and the stock responded with roughly +20% gains in 2021 as investors believed in the growth-through-M&A thesis and post-COVID demand tailwinds.
Then 2022 arrived and reset expectations. A ~22% annual decline reflected a sharp re-rating: the market stopped caring about deal velocity and started asking harder questions about integration, margin recovery, and whether all this M&A would actually work. Pet nutrition and fine fragrance required new capacity, new systems, new discipline. The conversation shifted from growth hype to execution risk.
The company pressed ahead. Early 2022 brought Wing Pet Food and Schaffelaarbos; Groupe Neroli and SFA Romani followed, consolidating pet assets under a dedicated unit. But the stock spent 2023 and 2024 in a choppy sideways grind—investors wanted proof that integration was delivering, that organic profitability could recover, that the portfolio actually hung together.
By 2025, another significant down leg (~19% annual) suggested patience had worn thin. Mixed operational beats and management changes toward year-end didn't fully reset sentiment. What emerged instead was a more cautious view: Symrise as a strategic compounder, yes, but one prone to shorter-term volatility and occasional underperformance. Valuation scrutiny intensified.
Into early 2026, the stock has found some footing again—wide swings remain, but it's trading above recent lows while still well below its multi-year peak. The technical picture shows a company that's proven it can buy, but still answering whether it can compound.
Key risks and downside factors
Symrise operates in a consolidated global market for flavors, fragrances and active ingredients where a handful of dominant players—Givaudan, IFF, DSM-Firmenich—alongside regional specialists like MANE and Takasago set the terms on pricing, R&D investment and customer access. The company faces mounting pressure from these scaled competitors and from a wave of innovation driven by biotech and precision fermentation, which are beginning to erode the economics of traditional natural-sourcing models. Its geographic spread across Europe, North America and Asia supports growth but leaves it exposed to raw-material volatility, currency fluctuations and the compounding risks of managing supply chains across multiple regions.
- Consolidation among much larger competitors—Givaudan, IFF, DSM-Firmenich—creates meaningful pressure on margins and customer negotiating power [3][5].
- Biotech and precision-fermentation players are entering the space with specialized ingredients that can replace traditional natural sources, which is compressing the product differentiation that incumbents once relied on.
- Raw-material and agricultural input costs remain volatile, while sustainability and regulatory sourcing requirements continue to layer on compliance burdens and push prices higher.
- Multi-regional operations expose the company to meaningful currency fluctuations, logistics bottlenecks, and supply-chain disruption across Europe, North America, and Asia [4][5].
Competitive landscape
Symrise trades as SY1 on XETRA in a concentrated market dominated by larger players like Givaudan and IFF, where it competes across flavors, fragrances, and specialty ingredients. The business faces margin pressure from scale advantages held by competitors, while exposure to natural-ingredient supply volatility and tightening sustainability and regulatory requirements create ongoing capital demands. These dynamics—scale disadvantage, input cost unpredictability, and rising compliance costs—are the real stress points to watch.
| Company | Ticker |
|---|---|
| Givaudan S.A. | GIVN.VX |
| International Flavors & Fragrances, Inc. | IFF.NYSE |
Private competitors
- MANE SA
- Robertet Group
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Symrise AG
Relative Performance vs Benchmarks
| Period | Symrise AG | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +13.33% | +9.07% | +7.88% |
| 3M | +7.28% | +8.24% | -2.42% |
| 6M | +16.50% | +11.44% | +6.06% |
| 1Y | -20.09% | -24.27% | -49.24% |
| 3Y | -17.37% | -74.35% | -103.04% |
| 5Y | -20.60% | -81.96% | -111.90% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 30.2 | 1.8 | 3.0 | 8.1 |
| 1Y ago | 30.9 | 3.0 | 3.7 | 16.5 |
| 3Y ago | 38.8 | 2.5 | 4.1 | 34.5 |
| 5Y ago | 31.7 | 2.8 | 6.0 | 17.2 |
Frequently Asked Questions
Where is the Symrise AG stock traded?
What does Symrise AG do?
What are the key metrics for SY1.XETRA?
How has Symrise AG's stock price performed?
How is SY1.XETRA valued?
Does SY1.XETRA pay dividends?
What are the key risks when investing in SY1.XETRA?
- Consolidation among much larger competitors—Givaudan, IFF, DSM-Firmenich—creates meaningful pressure on margins and customer negotiating power [web:3][web:5].
- Biotech and precision-fermentation players are entering the space with specialized ingredients that can replace traditional natural sources, which is compressing the product differentiation that incumbents once relied on.
- Raw-material and agricultural input costs remain volatile, while sustainability and regulatory sourcing requirements continue to layer on compliance burdens and push prices higher.
- Multi-regional operations expose the company to meaningful currency fluctuations, logistics bottlenecks, and supply-chain disruption across Europe, North America, and Asia [web:4][web:5].
Who are the main competitors of Symrise AG?
- Givaudan S.A. (GIVN.VX)
- International Flavors & Fragrances, Inc. (IFF.NYSE)
When does Symrise AG report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 1.25 EUR | 1.65% | 1.25% |
| 2025 | 1.20 EUR | 1.14% | |
| 2024 | 1.10 EUR | 1.08% | |
| 2023 | 1.05 EUR | 0.97% | |
| 2022 | 1.02 EUR | 0.93% | |
| 2021 | 0.97 EUR | 0.89% | |
| 2020 | 0.95 EUR | 0.98% | |
| 2020 | 0.95 EUR | 1.02% | |
| 2019 | 0.90 EUR | 1.04% | |
| 2018 | 0.88 EUR | 1.23% | |
| 2017 | 0.85 EUR | 1.34% | |
| 2016 | 0.80 EUR | 1.40% | |
| 2015 | 0.75 EUR | 1.32% | |
| 2014 | 0.70 EUR | 1.84% | |
| 2013 | 0.65 EUR | 1.99% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 4.93B | 5.00B | 4.73B | 4.62B | 3.83B |
| Operating income (EBIT) | 609.30M | 717.80M | 559.36M | 503.98M | 558.96M |
| Net income | 249.30M | 478.20M | 340.47M | 280.01M | 374.92M |
| Free cash flow | 521.05M | 667.49M | 449.31M | 109.94M | 347.40M |
| Total assets | 8.11B | 8.32B | 7.85B | 7.78B | 6.64B |
| Equity | 3.72B | 3.98B | 3.63B | 3.55B | 3.19B |
| Net debt | 1.60B | 1.84B | 2.17B | 2.23B | 1.35B |
PWP Leeway UG (haftungsbeschränkt)
